Obstetrics and Gynecology
Atosiban Acetate Injection
product description
Chemical Composition:
Atosiban is a synthetic peptide that mimics the structure of oxytocin, allowing it to competitively inhibit oxytocin receptors on the uterine muscle, as well as those involved in the release of vasopressin, which plays a role in uterine contraction mechanisms.
Mechanism of Action:
By binding to oxytocin receptors, Atosiban prevents the action of oxytocin, a natural hormone responsible for stimulating uterine contractions. This blockade results in the relaxation of the uterus and the suppression of premature labor contractions.
Indications and Usage:
It is specifically indicated for the short-term treatment of preterm labor in pregnant women with a gestational age of 24 to 33 weeks, showing signs of contractions but without premature rupture of membranes or other contraindications to tocolytic therapy.
Administration and Dosage:
The treatment regimen typically starts with an intravenous loading dose, followed by a continuous infusion at a dose adjusted based on the clinical response. The total duration of treatment is generally limited to 48 hours.
Efficacy and Outcomes:
Clinical trials have demonstrated Atosiban's effectiveness in delaying preterm delivery, thereby potentially reducing the risks associated with prematurity for the newborn.
Side Effects:
Side effects are generally mild and may include nausea, vomiting, headache, and dizziness. It has a favorable safety profile compared to other tocolytics.
Contraindications and Precautions:
Atosiban should not be used in cases of known hypersensitivity to the active substance or any of the excipients. It is also contraindicated in certain conditions such as pre-eclampsia or eclampsia, where prolonging pregnancy might pose a risk to mother or fetus.